Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials
Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.
Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.
from CNN.com - RSS Channel https://ift.tt/xzKJbA9
via IFTTT
Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.
from CNN.com - RSS Channel https://ift.tt/xzKJbA9
via IFTTT
Comments
Post a Comment